Cash, cash equivalents and short-term investments were $959.9M as of December 31, 2024. Novocure (NVCR) reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2024.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR:
- Novocure price target raised to $46 from $34 at Evercore ISI
- Novocure price target raised to $42 from $28 at Piper Sandler
- Novocure price target raised to $38 from $30 at H.C. Wainwright
- Novocure price target raised to $33 from $28 at Leerink
- Morning Movers: Intel climbs following retirement of CEO Pat Gelsinger